AKBA achieved a dramatic financial turnaround with operating income swinging from -$50.5M to +$23.5M, indicating the company has reached operational profitability.
This represents a fundamental shift from a loss-making biotech to an operationally profitable company, with cash position more than tripling to $184.8M and stockholders' equity turning positive at $32.6M. The transformation suggests successful commercialization of their products, though net losses persist due to non-operating expenses, and increased R&D spending of $62.4M indicates continued investment in pipeline development.
AKBA underwent a remarkable financial transformation with operating income swinging $74M from negative to positive territory, while cash and equivalents surged 256% to $184.8M, indicating strong operational cash generation and potentially new financing. Total assets grew 71% to $376.6M and stockholders' equity turned positive for the first time, moving from -$49.2M to +$32.6M, though current liabilities doubled suggesting increased operational scale. The company maintained investment in growth with R&D expenses increasing 66% to $62.4M, while achieving near break-even with net losses narrowing dramatically from -$69.4M to just -$5.3M, signaling a successful transition from development-stage losses to near-profitability.
Capital expenditure jumped 781.8% — major investment cycle underway; assess returns on deployment.
Operating cash flow surged 267.2% — exceptional cash generation, highest quality earnings signal.
Cash position surged 256.4% — strong cash generation or capital raise providing significant financial cushion.
Equity base grew 166.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Current assets grew 122.2% — improving short-term liquidity or inventory/receivables build.
Current liabilities surged 101.4% — significant near-term obligations; verify ability to meet short-term debt.
Net income grew 92.3% — bottom-line growth signals improving overall business health.
Asset base grew 70.6% — expansion through organic growth, acquisitions, or capital deployment.
R&D investment increased 65.6% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →